BIOSYNGEN PTE. LTD. Mediaroom

Biosyngen Announces FDA Fast Track Designation for BST02 in Treatment of Liver Cancer

SINGAPORE, Feb. 1, 2024 /PRNewswire/ -- Biosyngen is proud to announce that its latest groundbreaki...

2024-02-01 17:41 1709

Biosyngen Announces FDA Fast Track Designation for BST02 in Treatment of Liver Cancer

Biosyngen's BST02, the World's First TIL Therapy for Liver Cancer, is Granted an IND Approval by FDA

SINGAPORE, Oct. 26, 2023 /PRNewswire/ -- On October 26, 2023, Biosyngen's TIL therapy BST02 for liv...

2023-10-26 18:18 1875

Biosyngen's BST02, the World's First TIL Therapy for Liver Cancer, is Granted an IND Approval by FDA

Biosyngen received the Asia Pacific Cell & Gene Therapy Excellence Awards (APCGTEA) 2023

SINGAPORE, Sept. 18, 2023 /PRNewswire/ -- On September 14, 2023, Biosyngen Pte Ltd (hereinafter ref...

2023-09-18 17:53 1457

Biosyngen received the Asia Pacific Cell & Gene Therapy Excellence Awards (APCGTEA) 2023

Biosyngen received FDA approval for Phase I/II Clinical Trials for BRL03, targeting Lung Cancer, Gastric Cancer and other advanced Solid Tumors

SINGAPORE, Sept. 11, 2023 /PRNewswire/ -- On September 9th, 2023, Biosyngen Pte Ltd (hereafter as "...

2023-09-11 14:53 1126

Biosyngen received FDA approval for Phase I/II Clinical Trials for BRL03, targeting Lung Cancer, Gastric Cancer and other advanced Solid Tumors

Biosyngen's First-in-class Cell Therapy BRG01 Receives FDA Fast Track Designation

SINGAPORE, July 12, 2023 /PRNewswire/ -- On July 6, 2023, Biosyngen received an official notificati...

2023-07-12 13:38 2672

Creating the China-Singapore Translational Medicine Center - Biosyngen's pursuit to be a leading player in the CGT industry globally hits new milestone.

SINGAPORE, July 12, 2023 /PRNewswire/ -- This is a model of cooperation between Singapore and China...

2023-07-12 10:32 2544

Creating the China-Singapore Translational Medicine Center - Biosyngen's pursuit to be a leading player in the CGT industry globally hits new milestone.

Immuno-oncology company Biosyngen opens new cell therapy GMP facility in Singapore

New state-of-the-art facility to develop immunotherapy assets to address unmet needs in cancer trea...

2023-06-29 17:14 2769

Immuno-oncology company Biosyngen opens new cell therapy GMP facility in Singapore

Biosyngen's Cell Therapy BRG01 Granted Orphan Drug Designation by the U.S. FDA for Treatment of Nasopharyngeal Cancer

SINGAPORE, June 6, 2023 /PRNewswire/ -- Jun. 1st, 2023, Biosyngen Pte. Ltd. (hereinafter as "Biosyn...

2023-06-06 12:58 2487

Biosyngen's Cell Therapy BRG01 Granted Orphan Drug Designation by the U.S. FDA for Treatment of Nasopharyngeal Cancer

Biosyngen announces FDA IND approval of its second product for EBV-positive lymphoma

GUANGZHOU, China, April 18, 2023 /PRNewswire/ -- April 15, 2023, Biosyngen Pte Ltd (hereinafter as ...

2023-04-18 19:03 3098

Biosyngen announces FDA IND approval of its second product for EBV-positive lymphoma

Biosyngen received China NMPA IND approval for its T-cell redirection therapy targeting EBV-positive Lymphoma

GUANGZHOU, China, April 11, 2023 /PRNewswire/ -- April 7th, 2023, Biosyngen Pte Ltd (hereinafter as...

2023-04-11 18:09 2142

Biosyngen received China NMPA IND approval for its T-cell redirection therapy targeting EBV-positive Lymphoma

PM Lee receives a first-hand update by Biosyngen on its progress in cell therapy

GUANGZHOU, China, March 29, 2023 /PRNewswire/ -- The city of Guangzhou welcomes Singapore Prime Min...

2023-03-29 22:53 2762

PM Lee receives a first-hand update by Biosyngen on its progress in cell therapy

Biosyngen has obtained FDA IND clearance of BRG01 for Phase I/II clinical trials against Nasopharyngeal Cancer

SINGAPORE, Feb. 17, 2023 /PRNewswire/ -- February 16th, 2023, Biosyngen Pte Ltd (hereinafter as "Bi...

2023-02-17 23:13 7342

Biosyngen has obtained FDA IND clearance of BRG01 for Phase I/II clinical trials against Nasopharyngeal Cancer

IND Application of Biosyngen's Cell Therapy (BRG01) for Nasopharyngeal Cancer Approved by China NMPA

GUANGZHOU, China , Dec. 15, 2022 /PRNewswire/ -- On Dec. 14th, 2022, Guangzhou Biosyngen Co., Ltd. ...

2022-12-15 13:08 3672

IND Application of Biosyngen's Cell Therapy (BRG01) for Nasopharyngeal Cancer Approved by China NMPA

The IND application of Biosyngen BRG01 Therapy was accepted by CDE

GUANGZHOU, China, Sept. 28, 2022 /PRNewswire/ -- The IND application of Biosyngen BRG01 Therapy has...

2022-09-28 18:05 3282

Biosyngen Gives Cell Therapy GMP Capabilities in Singapore A Boost

SINGAPORE, Sept. 28, 2022 /PRNewswire/ -- On September 22nd, Biosyngen signed to set up a Cell The...

2022-09-28 17:34 4200

Biosyngen Gives Cell Therapy GMP Capabilities in Singapore A Boost

Embracing Win-win Cooperation - ASEAN Consul Generals, officials and representatives of chambers of commerce in Guangzhou visited Biosyngen

GUANGZHOU, China, May 28, 2022 /PRNewswire/ -- On the morning of May 27, 2022, Mr.Loh Tuck Keat, Co...

2022-05-28 09:00 6643

Latest News